Jupiter Wellness Completes Enrollment in Double-Blind Placebo-Controlled Clinical Trial of JW-200 for the Treatment of Actinic Keratosis
Data expected Q1 2022 on efficacy of JW-200 to clear AK lesions, a common form of pre-cancerous growth that left untreated can lead to cancer in up to 15% of patients JUPITER, FL / February 18, 2022 / Jupiter Wellness, Inc. (NASDAQ:JUPW) today announced it has completed recruitment in its clinical trial of JW-200 for […]